Laser Photocoagulation to Treat Macular Soft Drusen in Age-Related Macular Degeneration

Figueroa, Marta S.; Regueras, A; Bertrand, Josefina

doi:10.1097/00006982-199414050-00001

Cited by 75 publications

(32 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[8][9][10][11][12][13] These trials confirmed the anecdotal observations that laser photocoagulation to the macula caused the disappearance of drusen. Color fundus imaging confirmed these observations.…”

Section: Introductionsupporting

confidence: 68%

Change in Drusen Volume as a Novel Clinical Trial Endpoint for the Study of Complement Inhibition in Age-related Macular Degeneration

Filho¹,

Yehoshua²,

Gregori³

et al. 2014

Ophthalmic Surg Lasers Imaging Retina

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVE:To evaluate the change in drusen volume following treatment with eculizumab, a systemic inhibitor of complement component 5. PATIENTS AND METHODS:Single-center, prospective, randomized, double-masked clinical trial. Patients were randomized 2:1 to receive intravenous eculizumab or placebo over 26 weeks. Main outcome measure: decrease in drusen volume of at least 50% at 26-week follow-up. RESULTS:Mean drusen cube root volumes were 0.49 mm and 0.47 mm (P = .64) at baseline and 0.51 mm and 0.42 mm (P = .17) at 26 weeks in the eculizumab and placebo groups, respectively. In the placebo group, one eye had a decrease in drusen volume of at least 50% and two eyes developed neovascularization through 26 weeks. CONCLUSION:Systemic complement inhibition with eculizumab did not significantly reduce drusen volume. Drusen growth was dependent on the number of complement at-risk alleles. Future trials should consider the use of a composite clinical trial endpoint in which efficacy is defined by the treatment's ability to prevent drusen growth, neovascularization, and the formation of geographic atrophy over 1 year.

show abstract

Section: Introductionsupporting

confidence: 68%

Change in Drusen Volume as a Novel Clinical Trial Endpoint for the Study of Complement Inhibition in Age-related Macular Degeneration

Filho¹,

Yehoshua²,

Gregori³

et al. 2014

Ophthalmic Surg Lasers Imaging Retina

View full text Add to dashboard Cite

show abstract

“…Na ocasião, a porcentagem de pacientes cuja perda foi de seis ou mais linhas de visão foi de 20% no grupo tratado e 37% no grupo não tratado (16) . Tratamento preventivo com fotocoagulação a "laser" nas drusas moles tem surgido como uma nova opção terapêutica da degeneração macular relacionada à idade no sentido de se prevenir o aparecimento de membrana neovascular coroidal e tem sido avaliado numa série de ensaios clínicos (17)(18)(19)(20)(21) . Apesar dos resultados promissores na sua fase inicial em reabsorver as drusas moles com a fotocoagulação a "laser", parece que esse tratamento não impede o aparecimento da membrana neovascular coroidal no decorrer de alguns anos, como foi observado no ensaio multicêntrico randomizado (Choroidal Neovascularization Prevention Trial) que mostrou uma incidência aumentada de membrana neovascular coroidal em curto prazo nesses olhos de alto risco (22)(23) .…”

Section: N T R O D U ç ã Ounclassified

Degeneração macular relacionada à idade: modalidades terapêuticas

Farah¹,

Oshima²,

Costa³

et al. 2001

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

“…Nowadays, it is becoming evident that the available techniques for laser photocoagulation of choroidal neovascular membranes due to AMD will not have a major impact on blindness due to AMD, despite early expectations 24,27,34,35 . Prevention therapy with laser photocoagulation of soft drusen emerged as an alternative form of treatment, evaluated by a series of clinical trials [36][37][38][39][40] . Despite the initial observation that laser photocoagulation could cause large soft drusen to disappear, (which have been showed to be high risk for CNV 11,12,41 ), a large randomized, multicenter trial (Choroidal Neovascularization Prevention Trial) revealed that laser treatment to high risk eyes may increase the shortterm incidence of CNV 40,44 .…”

Section: Available Treatments For Amdmentioning

confidence: 99%

Benzoporphyrin (verteporfin) photodynamic therapy for choroidal neovascularization in age-related macular degeneration

Lucena¹,

Miller²

2000

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

Purpose: To review and discuss the available treatments for choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) emphasizing to photodynamic therapy (PDT).Methods: Published papers from 1974 until 1999 related to AMD, its available treatments and PDT were reviewed.Results: The most used effective treatment for CNV is laser photocoagulation which does not have a major impact on the blindness due to AMD.

show abstract

Laser Photocoagulation to Treat Macular Soft Drusen in Age-Related Macular Degeneration

Cited by 75 publications

References 0 publications

Change in Drusen Volume as a Novel Clinical Trial Endpoint for the Study of Complement Inhibition in Age-related Macular Degeneration

Change in Drusen Volume as a Novel Clinical Trial Endpoint for the Study of Complement Inhibition in Age-related Macular Degeneration

Degeneração macular relacionada à idade: modalidades terapêuticas

Benzoporphyrin (verteporfin) photodynamic therapy for choroidal neovascularization in age-related macular degeneration

Contact Info

Product

Resources

About